Navigation Links
Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Date:8/31/2009

PARIS, August 31 /PRNewswire-FirstCall/ --

- SEPIA-ACS Multiple-Dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet -

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy. The results of the SEPIA-ACS1/ TIMI-42 were presented today at the plenary session of the Annual European Society of Cardiology congress in Barcelona and simultaneously published online in The Lancet.

Otamixaban is a first in class, rapid onset antithrombotic compound, acting as a direct selective inhibitor of factor Xa. Otamixaban is originating from sanofi-aventis world-class thrombosis research portfolio and is currently in phase IIb clinical development phase.

"The data show that intermediate dosages of otamixaban may offer substantial reduction in major coronary complications in patients presenting with acute coronary syndrome, with bleeding rate comparable to current therapy," said Dr Marc Sabatine, MD, MPH, an Investigator in the TIMI Study Group and a cardiologist at Brigham and Women's Hospital, Harvard Medical School. "This research is addressing an important medical need, by potentially significantly improving outcomes of ACS patients undergoing PCI while simplifying the treatment pattern of the acute management phase of the disease," he added.

The double-blind phase
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
2. Sanofi-aventis Stands Behind the Safety of Lantus(R)
3. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
4. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
5. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
8. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
9. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
10. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
11. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Roughly three-quarters of pharmacists said they ... interchangeable biosimilar for its branded biologic counterpart if ... according to a survey published in the Academy ... Managed Care & Specialty Pharmacy (JMCP). ... would feel as confident if the products had ...
(Date:2/27/2015)... -- Pomerantz LLP is investigating claims on behalf of investors ... VTAE ).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... February 27, 2015, the Company announced that its partner ...
(Date:2/27/2015)... TEL-AVIV , Israele, February 27, 2015 /PRNewswire/ ... continua nel suo sviluppo dell,innovativo sistema di monitoraggio ... il primo trial sull,uomo-   ... operante nello sviluppo di nuovo sistema per il ... congestizio (CHF), ha annunciato oggi di aver concluso ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
(Date:3/1/2015)... 2015 A federal court overseeing ... scheduled to go to trial in October has ... to provide testimony regarding the role an Italian ... Profemur device, Bernstein Liebhard LLP comments. According to ... District of Iowa on February 25th, Wright Medical ...
(Date:3/1/2015)... 01, 2015 The number of transvaginal ... the past few weeks in two New Jersey litigations ... claims, the Firm announces. , A Case List ... the Bergen County proceeding established for products manufactured by ... few weeks earlier, when 90 fewer cases had been ...
(Date:3/1/2015)... 2015 ERISAPros is pleased ... Roddy to the professional staff of its Compliance Department. ... The Ohio State University-Mortiz College of Law. Prior to ... working with several Fortune 500 companies as well as ... corporate benefits. Her experiences range from benefit plan design, ...
(Date:3/1/2015)... Theme and plugin developers from Pixel Film ... for Final Cut Pro X entitled Transccordion. , “Transccordion ... FCPX editors project.” Said Christiana Austin, CEO of Pixel ... to easily drag and drop their accordion transition between ... controls over the parameters of this transition bundle and ...
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims ... platform and gears towards the goal for a better ... group talks in smaller groups will be held after ... Development, Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, Women and ... youths. , Young adults aged between 18-30 ...
Breaking Medicine News(10 mins):Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... 2011 Horst Sievert, MD, PhD, a renowned ... O. Hartzler Master Clinical Operator Award in a ... Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the ... given each year to a physician who has ...
... Nov. 11 (HealthDay News) -- Age-related declines in physical ... a new study. "The more income and assets ... co-author Virginia Richardson, a professor of social work at ... The researchers analyzed data from roughly 6,500 participants ...
... -- ,Helping others can reduce cravings for alcohol and ... study suggests. Such cravings are major causes of ... noted. The study included 93 male and 102 ... courts for substance abuse treatment at a large facility ...
... a new oral cholera vaccine developed through the ... by the United Nations and based in Seoul, ... (WHO). Developed for use in developing countries ... to use in a single-dose vial and is ...
... using stem cells, in the hope to replace damaged ... for application in other degenerative conditions. Drs Clare ... Florey Neuroscience Institutes and the University of Melbourne. They ... collaboration being launched at the University of Melbourne today. ...
... Although it can be prevented with a vaccine, roughly 90 ... flu each year, resulting in about 1 million hospital admissions, ... online edition of The Lancet , the research also ... 111,500 children in 2008. According to the report, 99 percent ...
Cached Medicine News:Health News:Horst Sievert, M.D., Ph.D. presented with Master Clinical Operator Award at TCT 2011 2Health News:Helping Others Helps Teens Beat Substance Abuse 2Health News:IVI announces the prequalification of innovative cholera vaccine by the World Health Organization 2Health News:IVI announces the prequalification of innovative cholera vaccine by the World Health Organization 3Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 3
... Now you can perform stereotactic, ultrasound ... the convenience of your office. Use the ... safer, easier and more clinically advanced method ... its best for the women who trust ...
... perform stereotactic, ultrasound and MRI-guided vacuum assisted ... office. Use the patented, FDA-cleared ATEC system ... clinically advanced method of breast biopsy. Its ... women who trust YOU.,9 Gauge Handpieces: Useful ...
Three-spring evacuator kits with silicone drains, 10 in. hole pattern, trocar and Y-connector tubing...
Offers a more constant suction profile than three-spring evacuators, resulting in the potential for improved tissue approximation and reduced risk of hematoma....
Medicine Products: